Literature DB >> 23689580

C3 glomerulopathy.

Aude Servais1, Laure-Hélène Noël, Véronique Frémeaux-Bacchi, Philippe Lesavre.   

Abstract

C3 glomerulopathy is a recent disease classification comprising several rare types of glomerulonephritis, including dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). The most common histological feature in these diseases is the presence of glomerular deposition of C3 within the mesangium and along the glomerular basement membrane (GBM) in the subendothelial area or within the GBM. The key role of complement alternative pathway (AP) in these disorders has been recently shown with the identification of acquired or genetic abnormalities. Low serum C3 level but normal C4 is a common finding. The acquired AP dysregulation in DDD and C3GN may be first induced by C3 nephritic factor (C3NeF). C3NeF activity is found in approximately 80% of patients with DDD and in 45% of patients with C3GN. The correlation with the complement is further supported by the detection of homozygous or heterozygous mutations in the regulatory complement proteins factor H (CFH), factor I (CFI), or C3. The genetic background of the patients may also influence the disease manifestation since common genetic variants including single nucleotide polymorphisms in the CFH, C3 and CFHR5 genes are associated with DDD and one at-risk MCP haplotype have been found to be significantly increased in C3GN. C3 glomerulopathies can present over a broad age range. DDD is more often diagnosed in children and age at diagnosis is significantly higher for patients with C3GN. Presenting features comprise any of proteinuria, hematuria, hypertension and renal failure. These glomerulonephritides are associated with chronic deterioration of renal function, leading to ESRD within 10 years of the diagnosis in 36-50% of patients. Outcomes of renal transplantation are characterized by histological recurrence which may contribute to increased rates of allograft failure. Administration of recombinant FH if it becomes available or replacement of FH via plasma exchange may be efficacious in the cases of FH deficiency. However, therapeutic inhibition of complement C3 and C5 is the main perspective.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23689580     DOI: 10.1159/000348654

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  13 in total

1.  A novel method for direct measurement of complement convertases activity in human serum.

Authors:  A M Blom; E B Volokhina; V Fransson; P Strömberg; L Berghard; M Viktorelius; T E Mollnes; M López-Trascasa; L P van den Heuvel; T H Goodship; K J Marchbank; M Okroj
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

2.  Defining the complement biomarker profile of C3 glomerulopathy.

Authors:  Yuzhou Zhang; Carla M Nester; Bertha Martin; Mikkel-Ole Skjoedt; Nicole C Meyer; Dingwu Shao; Nicolò Borsa; Yaseelan Palarasah; Richard J H Smith
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-23       Impact factor: 8.237

3.  Clinical findings, pathology, and outcomes of C3GN after kidney transplantation.

Authors:  Ladan Zand; Elizabeth C Lorenz; Fernando G Cosio; Fernando C Fervenza; Samih H Nasr; Manish J Gandhi; Richard J H Smith; Sanjeev Sethi
Journal:  J Am Soc Nephrol       Date:  2013-12-19       Impact factor: 10.121

Review 4.  C3 glomerulopathy - understanding a rare complement-driven renal disease.

Authors:  Richard J H Smith; Gerald B Appel; Anna M Blom; H Terence Cook; Vivette D D'Agati; Fadi Fakhouri; Véronique Fremeaux-Bacchi; Mihály Józsi; David Kavanagh; John D Lambris; Marina Noris; Matthew C Pickering; Giuseppe Remuzzi; Santiago Rodriguez de Córdoba; Sanjeev Sethi; Johan Van der Vlag; Peter F Zipfel; Carla M Nester
Journal:  Nat Rev Nephrol       Date:  2019-03       Impact factor: 28.314

Review 5.  Current Understanding of the Role of Complement in IgA Nephropathy.

Authors:  Nicolas Maillard; Robert J Wyatt; Bruce A Julian; Krzysztof Kiryluk; Ali Gharavi; Veronique Fremeaux-Bacchi; Jan Novak
Journal:  J Am Soc Nephrol       Date:  2015-02-18       Impact factor: 10.121

Review 6.  The role of the alternative pathway of complement activation in glomerular diseases.

Authors:  Emilia Łukawska; Magdalena Polcyn-Adamczak; Zofia I Niemir
Journal:  Clin Exp Med       Date:  2018-02-15       Impact factor: 3.984

7.  A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl.

Authors:  Nesrin Besbas; Bora Gulhan; Safak Gucer; Emine Korkmaz; Fatih Ozaltin
Journal:  J Nephrol       Date:  2013-12-05       Impact factor: 3.902

8.  Childhood-onset dense deposit disease: a rare cause of proteinuria.

Authors:  K Taranta-Janusz; A Wasilewska; B Szynaka
Journal:  Ir J Med Sci       Date:  2013-12-14       Impact factor: 1.568

Review 9.  C3 glomerulopathy and atypical hemolytic uremic syndrome: an updated review of the literature on alternative complement pathway disorders.

Authors:  Kultigin Turkmen; Ismail Baloglu; Hakan Ozer
Journal:  Int Urol Nephrol       Date:  2021-01-03       Impact factor: 2.370

10.  Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis.

Authors:  Melissa Inman; Ginnie Prater; Huma Fatima; Eric Wallace
Journal:  Clin Kidney J       Date:  2015-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.